Cargando…

No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination

PURPOSE: Silexan is an oral Lavender oil preparation with proven anxiolytic efficacy. Given the high prevalence of anxiety and restlessness in younger women, oral contraceptives and Silexan will likely be co-administered. METHODS: A double-blind, randomised, 2-period crossover study was performed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Heger-Mahn, Doris, Pabst, Günther, Dienel, Angelika, Schläfke, Sandra, Klipping, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269819/
https://www.ncbi.nlm.nih.gov/pubmed/25319228
http://dx.doi.org/10.1007/s40268-014-0065-5
_version_ 1782349395226787840
author Heger-Mahn, Doris
Pabst, Günther
Dienel, Angelika
Schläfke, Sandra
Klipping, Christine
author_facet Heger-Mahn, Doris
Pabst, Günther
Dienel, Angelika
Schläfke, Sandra
Klipping, Christine
author_sort Heger-Mahn, Doris
collection PubMed
description PURPOSE: Silexan is an oral Lavender oil preparation with proven anxiolytic efficacy. Given the high prevalence of anxiety and restlessness in younger women, oral contraceptives and Silexan will likely be co-administered. METHODS: A double-blind, randomised, 2-period crossover study was performed to investigate the effects of Silexan on the pharmacokinetics and pharmacodynamics of Microgynon(®), a combination oral contraceptive containing ethinyl estradiol 0.03 mg (EE) and levonorgestrel 0.15 mg (LNG) in healthy, fertile, adult females. During 2 consecutive cycles of 28 days, oral contraception was given for 21 days combined with 1 × 160 mg/day Silexan or placebo. Plasma concentration–time profiles of EE and LNG were obtained on day 18 ± 1 up to 24 h after dosing. The primary outcome measure was the area under the concentration–time curve over a dosing interval of τ = 24 h (AUCτ) for EE and LNG plasma levels. An interaction with Silexan was formally excluded if the 90 % confidence interval for the AUCτ ratio during co-administration with Silexan or placebo was included within the range of 0.80–1.25. Secondary outcomes included EE and LNG peak concentration (C (max)) and time to C (max) (t (max)), follicle size, endometrial thickness, the Hoogland score, and serum levels of estradiol, progesterone, and sex hormone-binding globulin. RESULTS: A total of 24 women (mean age 27.3 years; mean body mass index 22.2 kg/m(2)) participated. The confidence intervals for the EE and LNG AUCτ and C (max) ratios fell within the pre-specified limits, indicating no interaction (point estimates [Silexan/placebo] AUCτ EE 0.97, LNG 0.94; C (max) EE 0.99, LNG 0.96). For LNG, t (max) was slightly delayed. No secondary outcome indicated any impairment of contraceptive efficacy. CONCLUSIONS: Co-administration of Silexan did not affect the efficacy of a combination oral contraceptive containing EE and LNG and was well tolerated.
format Online
Article
Text
id pubmed-4269819
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-42698192014-12-22 No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination Heger-Mahn, Doris Pabst, Günther Dienel, Angelika Schläfke, Sandra Klipping, Christine Drugs R D Original Research Article PURPOSE: Silexan is an oral Lavender oil preparation with proven anxiolytic efficacy. Given the high prevalence of anxiety and restlessness in younger women, oral contraceptives and Silexan will likely be co-administered. METHODS: A double-blind, randomised, 2-period crossover study was performed to investigate the effects of Silexan on the pharmacokinetics and pharmacodynamics of Microgynon(®), a combination oral contraceptive containing ethinyl estradiol 0.03 mg (EE) and levonorgestrel 0.15 mg (LNG) in healthy, fertile, adult females. During 2 consecutive cycles of 28 days, oral contraception was given for 21 days combined with 1 × 160 mg/day Silexan or placebo. Plasma concentration–time profiles of EE and LNG were obtained on day 18 ± 1 up to 24 h after dosing. The primary outcome measure was the area under the concentration–time curve over a dosing interval of τ = 24 h (AUCτ) for EE and LNG plasma levels. An interaction with Silexan was formally excluded if the 90 % confidence interval for the AUCτ ratio during co-administration with Silexan or placebo was included within the range of 0.80–1.25. Secondary outcomes included EE and LNG peak concentration (C (max)) and time to C (max) (t (max)), follicle size, endometrial thickness, the Hoogland score, and serum levels of estradiol, progesterone, and sex hormone-binding globulin. RESULTS: A total of 24 women (mean age 27.3 years; mean body mass index 22.2 kg/m(2)) participated. The confidence intervals for the EE and LNG AUCτ and C (max) ratios fell within the pre-specified limits, indicating no interaction (point estimates [Silexan/placebo] AUCτ EE 0.97, LNG 0.94; C (max) EE 0.99, LNG 0.96). For LNG, t (max) was slightly delayed. No secondary outcome indicated any impairment of contraceptive efficacy. CONCLUSIONS: Co-administration of Silexan did not affect the efficacy of a combination oral contraceptive containing EE and LNG and was well tolerated. Springer International Publishing 2014-10-16 2014-12 /pmc/articles/PMC4269819/ /pubmed/25319228 http://dx.doi.org/10.1007/s40268-014-0065-5 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research Article
Heger-Mahn, Doris
Pabst, Günther
Dienel, Angelika
Schläfke, Sandra
Klipping, Christine
No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination
title No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination
title_full No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination
title_fullStr No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination
title_full_unstemmed No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination
title_short No Interacting Influence of Lavender Oil Preparation Silexan on Oral Contraception Using an Ethinyl Estradiol/Levonorgestrel Combination
title_sort no interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combination
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269819/
https://www.ncbi.nlm.nih.gov/pubmed/25319228
http://dx.doi.org/10.1007/s40268-014-0065-5
work_keys_str_mv AT hegermahndoris nointeractinginfluenceoflavenderoilpreparationsilexanonoralcontraceptionusinganethinylestradiollevonorgestrelcombination
AT pabstgunther nointeractinginfluenceoflavenderoilpreparationsilexanonoralcontraceptionusinganethinylestradiollevonorgestrelcombination
AT dienelangelika nointeractinginfluenceoflavenderoilpreparationsilexanonoralcontraceptionusinganethinylestradiollevonorgestrelcombination
AT schlafkesandra nointeractinginfluenceoflavenderoilpreparationsilexanonoralcontraceptionusinganethinylestradiollevonorgestrelcombination
AT klippingchristine nointeractinginfluenceoflavenderoilpreparationsilexanonoralcontraceptionusinganethinylestradiollevonorgestrelcombination